Firm at a glance
Charme Capital Partners is a platform private equity firm headquartered in Milan, Italy, with additional offices in London and Madrid, per its own website [S1].
What they buy
Based on publicly disclosed portfolio holdings, Charme Capital Partners appears to concentrate on healthcare and education sectors across Europe [S2]. The firm’s portfolio pattern suggests a focus on platform acquisitions in specialized service businesses, including diagnostic laboratories, medical device manufacturers, veterinary care providers, and specialized education facilities [S2]. Recent activity indicates an active add-on acquisition strategy to support platform growth, with three add-on transactions completed in the trailing twelve months [S2].
Portfolio
Healthcare
Charme Capital Partners’ healthcare portfolio includes Bianalisi, a diagnostic laboratory platform [S2], Prism Healthcare, acquired in March 2022 [S2], Indiba, a medical device business acquired in February 2022 [S2], and Tema Sinergie, a biotech platform acquired in October 2022 [S2]. All four are reported as platform investments [S2].
Education and Care
The firm’s education holdings include Witherslack Group, a platform investment [S2], and Bright Futures Care, an education and care platform acquired in June 2023 [S2].
Veterinary Care
Animalia, a veterinary care platform, was acquired in July 2024 [S2].
Recent activity (last 24 months)
* February 2025: Acquisition of Bianalisi [S2]
* January 2025: Add-on acquisition of Behandlingsskolerne ApS [S2]
* January 2025: Add-on acquisition of Indiba Asia distributor [S2]
* October 2024: Add-on acquisition of Oxford product range from Joerns Healthcare UK [S2]
* July 2024: Acquisition of Animalia [S2]
How this firm fits a seller
Charme Capital Partners appears suited for owner-operators of specialized healthcare and education service businesses seeking a European buyer with multi-jurisdictional operational capabilities. The firm’s recent transaction history demonstrates an active buy-and-build approach, completing three add-on acquisitions in the twelve months preceding the data collection date [S2]. For sellers in diagnostic laboratories, medical devices, veterinary services, or specialized education, the firm’s existing platforms may represent potential consolidation opportunities. The presence of offices across Milan, London, and Madrid suggests geographic reach for cross-border European transactions [S1].
Sources
[S1] https://charmecapitalpartners.com (as of 2025-01-15)
[S2] https://charmecapitalpartners.com/news (as of 2025-01-15)
Frequently asked questions
Does Charme Capital Partners buy healthcare businesses?
Yes, healthcare represents a substantial portion of the firm’s publicly disclosed portfolio. Charme Capital Partners holds platform investments across diagnostic laboratories, medical devices, and biotech, including Bianalisi, Prism Healthcare, Indiba, and Tema Sinergie [S2]. Recent add-on activity in this sector includes the October 2024 acquisition of the Oxford product range from Joerns Healthcare UK [S2].
What companies has Charme Capital Partners acquired recently?
The firm’s most recent platform acquisition was Bianalisi in February 2025 [S2]. Prior to that, Charme Capital Partners acquired Animalia, a veterinary care platform, in July 2024 [S2]. The firm also completed add-on acquisitions including Behandlingsskolerne ApS in January 2025 and an Indiba Asia distributor in January 2025 [S2].
Where is Charme Capital Partners based and how big is the firm?
Charme Capital Partners is headquartered in Milan, Italy, with additional offices in London and Madrid [S1]. Fund size and assets under management were not publicly disclosed in available sources as of January 2025.
Is Charme Capital Partners still actively acquiring?
Yes, the firm appears actively engaged in acquisitions. Charme Capital Partners completed five transactions in the 24 months preceding February 2025, including two platform acquisitions and three add-on transactions [S2]. The most recent disclosed transaction was the Bianalisi acquisition in February 2025 [S2].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.